BMEANasdaqPharmaceutical PreparationsFiscal year ends December 31

Biomea Fusion, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$0.84−0.03 (-3.84%)

Close on Oct 19, 2026

Market cap: $60.46M
P/E (TTM): –
Dividend yield: –

Biomea Fusion, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Stock-Based Compensation	9.52	19	14	10	6.23	0.32	–
Change in Accounts Payable	-9.70	6.09	2.56	2.96	0.64	0.42	-0.10
Operating Cash Flow	-70	-120	-97	-62	-35	-4.46	-1.28
Capital Expenditures	–	-0.36	-3.37	-1.03	-3.17	-0.05	–
Purchase of Investments	–	–	–	–	-38	–	–
Sale & Maturity of Investments	–	–	1.15	28	8.31	–	–
Investing Cash Flow	–	-0.36	-2.22	27	-33	-0.05	–
Stock Issued	4.91	–	162	–	–	10	1.44
Financing Cash Flow	68	1.67	164	1.24	153	66	1.44
Net Change in Cash	-2.47	-119	65	-34	84	61	0.16
Free Cash Flow	–	-120	-100	-63	-39	-4.51	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -152.4%

Financial strength

Current ratio: 3.47
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 332.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 4.98
Dividend yield: –